Cefoxitin Sodium for Injection

Cefoxitin Sodium for Injection kills bacteria by inhibiting bacterial cell wall synthesis, and due to its structural characteristics, it has a high resistance to β-lactamase produced by bacteria. Some common clinical Gram-positive, Gram-negative aerobic and anaerobic pathogens are highly sensitive to this product. Cefoxitin Sodium for Injection is resistant to Pseudomonas aeruginosa, most strains of Enterococcus, and Escherichia coli.

The main ingredient of this product is cefoxitin sodium, and its other scientific name is: (6R,7S)-3-carbamoyloxymethyl-7-methoxy-8-oxo-7-[2(2-thienyl)acetylamino]-5-thia-1-azabicyclo-[4.2.0]oct-2-ene-2-carboxylic acid sodium salt.

This product is white or off-white powder with a slight special odor.

It is suitable for the following infections caused by bacteria that are sensitive to this product: 1. Upper and lower respiratory tract infections. 2. Urinary tract infections including uncomplicated gonorrhea. 3. Peritonitis and other intra-abdominal and intra-pelvic infections. 4. Sepsis (including typhoid fever). 5. Gynecological infections. 6. Bone and joint soft tissue infections. 7. Endocarditis. Since this product is effective against anaerobic bacteria and stable against β-lactamase, it is particularly suitable for mixed aerobic and anaerobic infections, as well as infections caused by bacteria that produce β-lactamase and are sensitive to this product.

Intramuscular injection, intravenous injection or intravenous drip. The common dosage for adults is 1-2g/time, once every 6-8 hours. Or adjust the dosage according to the sensitivity of the pathogen and the condition. For patients with renal insufficiency, adjust the dosage according to the creatinine clearance rate. This product is used for intramuscular injection, each gram is dissolved in 2ml of 0.5% lidocaine hydrochloride; for intravenous injection, each gram is dissolved in 10ml of sterile water for injection; for intravenous drip, 1-2g of cefoxitin sodium is dissolved in 50ml or 100ml of normal saline or 5% or 10% glucose solution.

The adverse reactions of this product are mild. The most common local reactions: thrombophlebitis may occur after intravenous injection, and local induration and tenderness may occur after intramuscular injection. In addition, allergic reactions (rash, itching, eosinophilia, fever, dyspnea, etc.), hypotension, diarrhea, nausea, vomiting, leukopenia, thrombocytopenia, anemia, and transient increases in ALT, AST, ALP, LDH, BUN or serum Cr values are occasionally seen.

Patients who are allergic to this product and cephalosporin antibiotics are contraindicated.

Not yet clear.

Keep in a dark and airtight container in a cool and dry place. Validity period: 24 months

1.0g (calculated as C16H17N3O7S2)

24 months.

Honz Pharmaceutical Co., Ltd.

• Founded in:

  1994-01-20

• Address:

  No. 6, Yaogu 3rd Road, Yaogu Industrial Park, Haikou National High-tech Industrial Development Zone, Hainan Province

• Tax NO.:

  91460000708873536T

• Registered Funds:

  455.124411 yuan

• Website:

  Log in to view

• Email:

  Log in to view